AC Immune/ACIU

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About AC Immune

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Ticker

ACIU

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Andrea Pfeifer

Employees

133

Headquarters

Lausanne, Switzerland

AC Immune Metrics

BasicAdvanced
$461M
Market cap
-
P/E ratio
-$0.68
EPS
1.30
Beta
-
Dividend rate
$461M
1.29742
$5.14
$1.90
822K
7.779
1.836
2.301
-32.45%
-36.68%
-35.04%
28.108
2.875
4.413
276.14%
26.07%
-1.38%

What the Analysts think about AC Immune

Analyst Ratings

Majority rating from 4 analysts.
Buy

AC Immune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
CHF 0
-100.00%
Net income
-CHF 18M
278.72%
Profit margin
0.00%
-100.00%

AC Immune Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 32.92%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-CHF 0.20
-CHF 0.18
-CHF 0.05
-CHF 0.18
-
Expected
-CHF 0.19
CHF 0.03
-CHF 0.11
-CHF 0.14
CHF 0.40
Surprise
3.67%
-754.26%
-54.25%
32.92%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for AC Immune stock?

AC Immune (ACIU) has a market cap of $461M as of June 20, 2024.

What is the P/E ratio for AC Immune stock?

The price to earnings (P/E) ratio for AC Immune (ACIU) stock is 0 as of June 20, 2024.

Does AC Immune stock pay dividends?

No, AC Immune (ACIU) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next AC Immune dividend payment date?

AC Immune (ACIU) stock does not pay dividends to its shareholders.

What is the beta indicator for AC Immune?

AC Immune (ACIU) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the AC Immune stock price target?

The target price for AC Immune (ACIU) stock is $10.59, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell AC Immune stock

Buy or sell AC Immune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing